Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Etsy Inc (ETSY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Etsy Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $299.01 (market cap $39.89B), while Etsy Inc trades at $81.14 (market cap $7.69B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 5.2× Etsy Inc's market cap, and Etsy Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.
| ALNY | ETSY | |
|---|---|---|
Market Cap | $39.89B | $7.69B |
Sector | Health | Consumer Cyclical |
52-Week High | $491.22 | $81.05 |
52-Week Low | $278.09 | $44.05 |
Enterprise Value | $38.15B | $9.34B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
ETSY trades at $81.05, up 4.28% recently, with a bullish technical outlook supported by positive moving averages and recent earnings beats. The company shows strong gross margins of 71.55% and positive cash flow trends, though net income declined to $162.98M in 2025. Analyst sentiment is mixed with 49% buy ratings but a consensus price target of $70.79 below current levels, highlighting valuation concerns amid competitive pressures.
Outlook remains cautious due to high P/E of 31.05 and negative shareholder equity, offset by operational improvements and AI-driven seller tools. Key risks include active buyer declines and heavy debt load, but sustained GMS growth and cost management could support recovery if execution strengthens.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Etsy Inc
Etsy operates a top-10 e-commerce marketplace operator in the U.S. and the U.K., with sizable operations in Germany, France, Australia, and Canada. The firm dominates an interesting niche, connecting buyers and sellers through its online market to exchange vintage and craft goods. With $13.5 billion in 2021 consolidated gross merchandise volume, the firm has cemented itself as one of the largest players in a quickly growing space, generating revenue from listing fees, commissions on sold items, advertising services, payment processing, and shipping labels. As of the end of 2021, the firm connected more than 96 million buyers and more than 7.5 million sellers on its marketplace properties: Etsy, Reverb (musical equipment), Elo7 (crafts in Brazil), and Depop (clothing resale).
Read more on ETSY →
